Kempen John H, Pistilli Maxwell, Begum Hosne, Fitzgerald Tonetta D, Liesegang Teresa L, Payal Abhishek, Zebardast Nazlee, Bhatt Nirali P, Foster C Stephen, Jabs Douglas A, Levy-Clarke Grace A, Nussenblatt Robert B, Rosenbaum James T, Sen H Nida, Suhler Eric B, Thorne Jennifer E
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA; MCM Eye Unit, MyungSung Christian Medical Center and Medical College, Addis Ababa, Ethiopia.
Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Am J Ophthalmol. 2021 Mar;223:377-395. doi: 10.1016/j.ajo.2019.03.024. Epub 2019 Apr 3.
To assess how often non-infectious anterior scleritis remits and identify predictive factors.
Our retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models.
During 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within ≤90 days was associated with more remission incidence.
Our results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed.
评估非感染性前巩膜炎缓解的频率,并确定预测因素。
我们在四个眼部炎症亚专业中心进行的回顾性队列研究,收集了自各中心成立(1978年、1978年、1984年、2005年)至2010年每次就诊时每个患眼/患者的数据。缓解定义为在至少连续三个月的所有就诊中或直至最后一次就诊(以避免对缓解后停止随访的患者进行删失)时,停用所有抑制性药物后疾病无活动。使用Cox回归模型评估可能预测缓解的因素。
在对832只患眼进行的总计1906年的随访中,214只眼(584例患者中的170例)出现缓解。巩膜炎缓解的中位时间 = 7.8年(95%置信区间[CI]:5.7,9.5)。随访期间,缓解更多地发生在早期而非晚期。预测巩膜炎缓解较少的因素包括巩膜炎双侧性(调整后风险比[aHR] = 0.46,95%CI:0.32 - 0.65);诊断为任何全身性炎症性疾病(aHR = 0.36,95%CI:0.23 - 0.58),或具体为类风湿关节炎(aHR = 0.22),或肉芽肿性多血管炎(aHR = 0.08)。在≤90天内使用他汀类药物治疗(aHR = 1.53,95%CI:1.03 - 2.26)与更高的缓解发生率相关。
我们的结果表明,前巩膜炎的缓解比新诊断的前葡萄膜炎或慢性前葡萄膜炎发生得更慢,这表明在长期抑制后尝试逐渐减少抑制性药物是有必要的。当存在全身性炎症性疾病时,缓解的频率较低。需要对辅助性他汀类药物治疗是否真的能增强巩膜炎缓解(如此处所示)进行验证性研究。